MedTrace Logo

A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy Participants

NCT06555601 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2025-12-26

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and tolerability of a single ascending dose of UCB3101 in cohorts of healthy male and female study participants.

Conditions

  • Healthy Participants

Interventions

DRUG

UCB3101

Study participants will receive UCB3101 as prespecified in each cohort.

DRUG

Placebo

Study participants will receive placebo as prespecified in each cohort to maintain the blinding.

Sponsors & Collaborators

  • UCB Biopharma SRL

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2025-11-24
Completion
2025-11-24

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06555601 on ClinicalTrials.gov